Q4 2025 EPS Estimates for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Cut by Zacks Research

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Equities research analysts at Zacks Research lowered their Q4 2025 earnings estimates for shares of Catalyst Pharmaceuticals in a report released on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings per share of $0.65 for the quarter, down from their prior estimate of $0.66. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.81 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q1 2026 earnings at $0.76 EPS and FY2026 earnings at $3.45 EPS.

Several other equities research analysts also recently commented on the stock. Citigroup assumed coverage on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a “buy” rating and a $27.00 target price on the stock. TheStreet upgraded shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 12th. Oppenheimer reiterated an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. HC Wainwright reiterated a “buy” rating and set a $24.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, March 1st. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $26.43.

Catalyst Pharmaceuticals Trading Down 2.9 %

CPRX opened at $14.68 on Thursday. The company’s 50 day moving average is $15.50 and its 200-day moving average is $14.61. Catalyst Pharmaceuticals has a 1-year low of $11.09 and a 1-year high of $17.76. The company has a market cap of $1.73 billion, a P/E ratio of 24.07, a PEG ratio of 0.81 and a beta of 0.89.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%. The company had revenue of $110.57 million for the quarter, compared to the consensus estimate of $105.78 million.

Institutional Trading of Catalyst Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Catalyst Pharmaceuticals by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 7,120,417 shares of the biopharmaceutical company’s stock valued at $119,694,000 after acquiring an additional 73,930 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Catalyst Pharmaceuticals by 1.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,601,797 shares of the biopharmaceutical company’s stock valued at $43,738,000 after acquiring an additional 41,923 shares in the last quarter. Boston Partners increased its stake in shares of Catalyst Pharmaceuticals by 965.2% in the 4th quarter. Boston Partners now owns 1,541,660 shares of the biopharmaceutical company’s stock valued at $25,610,000 after acquiring an additional 1,396,930 shares in the last quarter. Opaleye Management Inc. increased its stake in Catalyst Pharmaceuticals by 4.3% during the 4th quarter. Opaleye Management Inc. now owns 1,257,200 shares of the biopharmaceutical company’s stock valued at $21,436,000 after purchasing an additional 52,200 shares in the last quarter. Finally, LSV Asset Management increased its stake in Catalyst Pharmaceuticals by 25.6% during the 3rd quarter. LSV Asset Management now owns 1,240,769 shares of the biopharmaceutical company’s stock valued at $14,505,000 after purchasing an additional 253,100 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total value of $411,000.00. Following the transaction, the insider now owns 124,433 shares in the company, valued at approximately $2,045,678.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 12.10% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.